Danish biotech Genmab has started new legal proceedings against Janssen relating to their license agreement for daratumumab, just a couple of months after losin 10 June 2022
Danish firm Genmab was trading nearly 4% lower on Friday afternoon after the company lost out in a dispute with the Johnson & Johnson subsidiary Janssen. 8 April 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.